This page provides study documentation for BA12. For description of the specimen results, see Specimen Results Description (open to public). Data sets of the specimen results are included in the existing WHI datasets located on the WHI Data on this site (sign in and a completed Data Distribution Agreement are required; see details on the Data site).
Investigator Names and Contact Information
Breast cancer and hip fracture are two of the four highlighted outcomes of the BAA solicitation and represent two of the leading causes of morbidity in postmenopausal women. Within the WHI Hormone Therapy Clinical Trial (WHI-HT), hormone therapy (HT) has been associated with a decrease in hip fracture independent of the type of therapy used. In contrast, regimens containing progestins were associated with a modest increase in breast cancer risk while estrogen-only regimens were not. The mechanisms underlying the relationships between HT and both breast cancer and hip fracture are not well-understood.
Some of the publications related to this ancillary study are: 916.
For a complete, up-to-date list of WHI papers related to this ancillary study, please use the searchable Bibliography section of this website. To search for papers by study number, access the Simple Search, and enter the study number in the “Related Studies” field.